Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans
Source: SeekingAlpha
2025-11-19 20:34:30 ET
More on Vivos Therapeutics
- Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript
- Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript
- Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Vivos Therapeutics
- Historical earnings data for Vivos Therapeutics
Read the full article on Seeking Alpha
For further details see:
Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans
Vivos Therapeutics Inc.
NASDAQ: VVOS
VVOS Trading
-0.22% G/L:
$1.342 Last:
24,503 Volume:
$1.30 Open:
VVOS Latest News
February 05, 2026 08:45:00 am
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies
January 20, 2026 05:31:09 pm
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
January 16, 2026 08:00:00 am
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
December 16, 2025 08:45:00 am
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
VVOS Stock Data
$16,280,184
8,040,995
N/A
7
N/A
Medical Equipment & Supplies
Healthcare
US
Littleton
